Form 4: Elicio Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Jay Venkatesan, a Director of Elicio Therapeutics, Inc., received 21,750 shares of common stock on August 31, 2026.
Summary
- Grant/award: acquired 21,750 Stock Option (Right to Buy) on August 31, 2026; holds 21,750 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jay Venkatesan — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-31 | Grant/award | Stock Option (Right to Buy) | 21,750 | — | — | 21,750 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-31 | Grant/award (21,750 shares) |
Keywords
insider transaction, Form 4, ELTX, Elicio Therapeutics, Inc., neutral, Jay Venkatesan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.